# Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

> **NCT00819013** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 87 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza A Vaccine: ACAM FLU-A
- **BIOLOGICAL:** Influenza A Vaccine: ACAM FLU-A
- **BIOLOGICAL:** Influenza A Vaccine: ACAM FLU-A
- **BIOLOGICAL:** Saline placebo

## Key facts

- **NCT ID:** NCT00819013
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-02
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2012-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819013, "Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00819013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*